HER2 Support Group Forums

HER2 Support Group Forums (http://her2support.org/vbulletin/index.php)
-   Clinical Trials (http://her2support.org/vbulletin/forumdisplay.php?f=29)
-   -   positive data from a Phase I clinical trial of carfilzomib (http://her2support.org/vbulletin/showthread.php?t=36270)

eric 10-26-2008 02:03 PM

positive data from a Phase I clinical trial of carfilzomib
Proteolix Reports Encouraging Results From Phase I Cancer Trial

Posted on: Sunday, 26 October 2008, 09:00 CDT
Proteolix has reported positive data from a Phase I clinical trial of carfilzomib in patients with advanced solid tumors.
The Phase I clinical trial was designed to assess the safety, pharmacokinetics and pharmacodynamics of carfilzomib among patients with advanced solid tumors who had previously failed at least two rounds of prior treatment with approved chemotherapies.
Patients received carfilzomib administered for two consecutive days for each of the first three weeks on a four-week cycle. Dosing commenced at 20mg/m2 and escalated thereafter to a dose of 36mg/m2.

A total of 14 patients were enrolled in the study. Of those, one renal cell patient who had previously failed three prior rounds of treatment achieved a partial response and remains on the study after eight months of treatment. One small cell lung cancer patient achieved stable disease and is continuing on study after six months, and a mesothelioma patient achieved stable disease for five months. Carfilzomib was generally well tolerated with a low incidence of grade three or higher adverse events.
Lori Kunkel, chief medical officer of Proteolix, said: "We believe carfilzomib exhibits strong potential in diverse cancer indications. Based on these encouraging results, we recently initiated a Phase II clinical trial evaluating carfilzomib's activity in four types of solid tumor cancers. In addition, we look forward to reporting data from our ongoing trials of carfilzomib in hematologic malignancies later this year."

Jackie07 11-01-2008 07:35 PM

"Novel proteasome inhibitor; also being evaluated in a Phase I trial in combination with Revlimid-dex."

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for a single active site in the proteasome with minimal cross reactivity to other protease classes. In addition to the ongoing clinical trials in multiple myeloma, Proteolix is evaluating carfilzomib as a single agent in a Phase 2 trial of patients with advanced solid tumors and in a Phase 1 study of lymphoma. Phase 1 clinical studies have shown that patients with hematologic malignancies who have relapsed or progressed following multiple therapies can achieve durable anti-tumor responses with carfilzomib.

All times are GMT -7. The time now is 08:42 AM.

Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2019, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007